drugset / Trial / NCT07708181
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
Timeline
- Start
- 2026-08-02
- Primary completion
- 2027-08-11
- Completion
- 2028-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Colchicine | Small molecule | 0.5 mg | — |
| Subject | SSGJ-613 | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | SSGJ-613 | Monoclonal antibody | 200 mg | Subcutaneous |